Among children (14 years or younger) and adolescents (15 to 19 years), overall cancer death rates have declined by 70 percent and 64 percent, respectively, between 1970 and 2020, driven largely by improvements in treatment (2). Among the major advances made across the clinical cancer care continuum from August 1, 2022, to July 31, 2023, are 14 new anticancer therapeutics approved for use by FDA (see Table 3, p. 77). During this period, FDA also approved new uses for 12 previously approved anticancer therapeutics (see Table 3, p. 77), two agents to improve quality of life for patients with cancer undergoing active treatment, two new imaging agents to help visualize cancerous cells during surgery (see Visualizing Lung Cancers More Precisely During Surgery, p. 78 and Imaging Prostate Cancer More Clearly, p. 82), and several artificial intelligence-based tools to improve detection and diagnosis of cancers (see Sidebar 24, p. 66). Collectively, advances such as these are helping increase the number of The Medical Research Community: Driving Progress Together Progress against cancer can be accelerated when all stakeholders dedicated to fundamentally changing the burden of cancer work together. Further increasing collaboration will invigorate future breakthroughs. The key stakeholders are: Adapted from (1). SAVING LIVES Individuals diagnosed with cancer, their caregivers, family members, and friends Health care systems and clinical teams Academic and government researchers from a diverse array of specialties Biotechnology, pharmaceutical, diagnostics, and medical device company research teams Individual citizen scientists, patient advocates, other cancer advocates, and members of advocacy groups Health insurance companies Federal funding organizations Regulators Policymakers Philanthropic organizations and individual donors, cancer-focused professional organizations, and cancer-focused foundations SIDEBAR 1 Cancer in 2023 AACR Cancer Progress Report 2023 13
RkJQdWJsaXNoZXIy NTkzMzk=